(Q36579400)

15 August 2017

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma (English)

1 reference

15 August 2017

0 references

0 references

Robert Niven

3

0 references

author name string

Edward Piper

1

1 reference

15 August 2017

Christopher Brightling

2

1 reference

15 August 2017

Chad Oh

4

1 reference

15 August 2017

Raffaella Faggioni

5

1 reference

15 August 2017

Kwai Poon

6

1 reference

15 August 2017

Dewei She

7

1 reference

15 August 2017

Chris Kell

8

1 reference

15 August 2017

Richard D May

9

1 reference

15 August 2017

Gregory P Geba

10

1 reference

15 August 2017

Nestor A Molfino

11

1 reference

15 August 2017

27 June 2012

1 reference

European Respiratory Journal

15 August 2017

1 reference

15 August 2017

41

1 reference

15 August 2017

2

1 reference

15 August 2017

330-338

1 reference

Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Lebrikizumab Treatment in Adults with Asthma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Increased sputum and bronchial biopsy IL-13 expression in severe asthma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Interleukin-13: central mediator of allergic asthma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354).

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Development and validation of a questionnaire to measure asthma control.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

Requirement for IL-13 independently of IL-4 in experimental asthma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561510

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

20 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22743678

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22743678

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1183/09031936.00223411

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22743678

1 reference